胸腺法新联合经鼻高流量湿化氧疗治疗重症肺炎合并呼吸衰竭的效果

Effect of Thymalfasin Combined with High-flow Nasal Cannula Oxygen Therapy in the Treatment of Severe Pneumonia Complicated with Respiratory Failure

目的:探讨胸腺法新联合经鼻高流量湿化氧疗(HFNC)治疗重症肺炎合并呼吸衰竭的效果。方法:将石家庄市人民医院2021年1月-2022年7月收治的96例重症肺炎合并呼吸衰竭患者作为研究对象,按照随机数字表法分为对照组和观察组,各48例。对照组在常规基础治疗上进行HFNC治疗,观察组在对照组治疗基础上给予胸腺法新治疗。观察两组临床疗效、治疗前后炎症介质水平、动脉血气指标。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组可溶性髓系细胞触发受体-1(sTREM-1)、高迁移率族蛋白-1(HMGB-1)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平均低于对照组,差异均有统计学意义(P<0.05);治疗后,观察组动脉血氧分压(PaO_(2))、血氧饱和度(SaO_(2))均高于对照组,差异均有统计学意义(P<0.05)。结论:胸腺法新联合HFNC治疗重症肺炎合并呼吸衰竭,可以提高临床疗效,减轻炎症反应,改善血氧含量。

Objective:To explore the effect of Thymalfasin combined with high-flow nasal cannula oxygen therapy(HFNC)in the treatment of severe pneumonia complicated with respiratory failure.Method:A total of 96 patients with severe pneumonia complicated with respiratory failure who were admitted to Shijiazhuang People's Hospital from January 2021 to July 2022 were taken as the research objects and divided into the control group and the observation group according to the random number table method,with 48 cases in each group.The control group was treated with HFNC on the basis of routine treatment,and the observation group was treated with Thymalfasin on the basis of control group.The clinical efficacy,before and after treatment of levels of inflammation mediators and arterial blood gas indicators were observed in the two groups.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of soluble triggering receptor expressed on myeloid cells-1(sTREM-1),high mobility group box proteinl(HMGB-1),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the arterial partial pressure of oxygen(PaO2)and arterial oxygen saturation(SaO2)in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Thymalfasin combined with HFNC in the treatment of severe pneumonia complicated with respiratory failure can improve clinical efficacy,reduce inflammatory reaction and improve blood oxygen content.